- An inducible cre deleter under the control of the BMX non-receptor tyrosine kinase promoter.
- Cre recombination is inducible via administration of tamoxifen.
- Useful for study of angiogenesis, atherosclerosis and neovascularization.
- Non-induced Bmx-CreERT2 mice demonstrate no Cre recombinase activity, while tamoxifen-induced Bmx-CreERT2 mice demonstrate high levels of recombinase-mediated gene deletion in endothelial cells (95%+).
Genetic Background: C57BL/6J
Origin: The Bmx-Cre-ERT2 mouse was developed in the laboratory of Ralf Adams at the London Research Institute. The model was generated by microinjecting a transgene containing a genomic Bmx promoter fragment fused to a CreERT2 cDNA into B6xCBA F1 zygotes. Founder lines were backcrossed to C57BL/6 for at least five generations. Taconic received embryos from CRT in 2015.
Source: Cancer Research Technology (CRT)